IDEXX Laboratories Company Profile (NASDAQ:IDXX)

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Tuesday, August, 1st. The company reported $0.95 EPS for the quarter, beating the Zacks' consensus estimate of $0.85 by $0.10. The firm earned $508.90 million during the quarter, compared to analysts' expectations of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. IDEXX Laboratories's revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.

6 analysts have issued 12 month target prices for IDEXX Laboratories' shares. Their forecasts range from $118.00 to $200.00. On average, they anticipate IDEXX Laboratories' share price to reach $171.60 in the next year. View Analyst Ratings for IDEXX Laboratories.

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

• 1. According to Zacks Investment Research, "Over the last six months, IDEXX has been trading below the broader industry. Also, the company’s high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation is also a concern. On a positive note, IDEXX continues to demonstrate solid growth globally on strong international expansion. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently widened its cloud technology portfolio by adding rVetLink.  Solid organic revenue growth along with a raised guidance for 2017 buoy optimism." (10/18/2017)
• 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Some companies that are related to IDEXX Laboratories include Astellas Pharma (ALPMY), Essilor International SA (ESLOY), Zimmer Biomet Holdings (ZBH), Cerner Corporation (CERN), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Cardinal Health (CAH), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Smith & Nephew SNATS (SNN), Centene Corporation (CNC), Align Technology (ALGN), Lonza Group Ag (LZAGY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN) and Eisai Co., Ltd (ESALY).

IDEXX Laboratories' management team includes the folowing people:

• Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
• Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
• Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
• Jay Mazelsky, Executive Vice President
• Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
• William T. End, Lead Independent Director
• Bruce L. Claflin, Independent Director
• Stuart M. Essig Ph.D., Independent Director
• Rebecca M. Henderson Ph.D., Independent Director
• Daniel M. Junius, Independent Director

IDEXX Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.25%), Robeco Institutional Asset Management B.V. (0.18%), Harvey Investment Co. LLC (0.12%), Wendell David Associates Inc. (0.04%), Bath Savings Trust Co (0.04%) and Denali Advisors LLC (0.03%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Harvey Investment Co. LLC, State Treasurer State of Michigan, Winslow Evans & Crocker Inc., Wendell David Associates Inc., Bath Savings Trust Co and Mutual of America Capital Management LLC. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Denali Advisors LLC, Robeco Institutional Asset Management B.V., Wealth Enhancement Advisory Services LLC, Hermes Investment Management Ltd., Oakbrook Investments LLC and LS Investment Advisors LLC. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDEXX Laboratories stock can currently be purchased for approximately $164.71.